Why the 2023 peptide compounding ban happened: the FDA's rationale

A plain-English read of why several peptides moved to Category 2 — and what the agency actually said.

TL;DR

• In late 2023, the FDA placed BPC-157, TB-500, ipamorelin (briefly), CJC-1295, and others on Category 2, which restricts 503A compounding.
• The rationale was data gaps and unresolved safety questions — not a finding that the peptides were dangerous.
• In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal. FDA removed 12 peptides, including BPC-157 and TB-500, from Category 2 on April 22, 2026.

What it is

The 503A compounding framework (in plain English: the federal rules that let small pharmacies make patient-specific medications) includes a list called the "bulk drug substances used in compounding under section 503A" list. The FDA assigns substances to one of three categories. Category 1 means the substance can be compounded while the agency considers it. Category 2 means it cannot be compounded. The agency cites either significant safety risks or insufficient data to evaluate the substance (FDA bulk drug substances list).

How it works

Think of the framework as a guest list at a restricted club. The Pharmacy Compounding Advisory Committee (PCAC) — a panel of pharmacists, physicians, and consumer representatives — reviews nominated substances and advises FDA on whether to add them to the Section 503A bulk drug substances list. The committee is advisory, and FDA makes the final decision. When a peptide moves from Category 1 to Category 2, the practical effect is that 503A pharmacies stop compounding it. The compound itself is not banned outright in research — it is removed from the list of substances permitted for pharmacy compounding.

Who asks about it

Patients and physicians come to this topic when a peptide they were using disappears from a pharmacy formulary. They want to know whether the FDA found something dangerous, whether the decision is permanent, and whether the compound is coming back.

What the research says

The FDA's published rationales for Category 2 decisions cite a few factors. Limited human safety data is one. Manufacturing quality concerns are another. The absence of an approved indication that would justify routine compounding is the third (PCAC meeting materials). For several peptides the agency wrote that "significant safety risks" may exist. For others it cited insufficient data. The distinction matters. Insufficient data is not the same as confirmed harm. Subsequent litigation has argued that decades of animal data should support Category 1 status for several compounds.

What to know before considering it

Category 2 status is not a permanent ban. It is a regulatory line that determines whether 503A pharmacies can compound the substance under current rules. FDA removed 12 peptides from Category 2 on April 22, 2026, after their nominations were withdrawn. It did not move them to Category 1. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. Material sold online as "research use only" remains gray-market and is not regulated for human use, regardless of any reclassification news.

The Halftime POV

The honest read of 2023 is that the FDA made a regulatory call with imperfect information, in a category where high-quality human data is genuinely sparse. The 2026 reclassification conversation reflects new information and changed political winds — not a finding that the original decision was wrong. We track Federal Register notices, not headlines.

Related reading:

• Category 1 vs Category 2 peptides: the access framework
• Secretary Kennedy's February 2026 remarks on peptides
• Why some peptides are still Category 2 after the 2026 reclassification news
• The PCAC advisory committee: what it is and why it matters

---

FAQ

Q: What was the 2023 peptide compounding ban? A: In late 2023, the FDA placed several peptides — including BPC-157, TB-500, ipamorelin (briefly), CJC-1295, and others — on its Category 2 list, which restricts compounding under section 503A. The agency cited safety data gaps and insufficient information on use as a bulk drug substance.

Q: Did the FDA say these peptides were unsafe? A: No. Category 2 status means the FDA flagged unresolved questions, not confirmed harm. The agency wrote that "significant safety risks" may exist or that data was insufficient to evaluate the substance under 503A — different from declaring a compound dangerous.

Q: What does the 2026 reclassification news mean? A: In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. FDA removed 12 peptides, including BPC-157 and TB-500, from Category 2 on April 22, 2026, after their nominations were withdrawn. The PCAC advisory committee met on July 23–24, 2026 and voted to recommend several of these peptides, including BPC-157 and TB-500, for the Section 503A bulk drug substances list. Final status changes through Federal Register publication.

---

Disclaimer

Several peptides discussed in this article were previously in FDA's Category 2. FDA removed them from Category 2 (September 2024 or April 2026, depending on the peptide). As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
• FDA, Pharmacy Compounding Advisory Committee (PCAC) — Meeting Materials

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.